# Test Results: literature/synthesis-across-papers.md

> ⚠️  Raw model output captured automatically by the cross-model test harness on 2026-06-25.
> This output is **not yet verified**. An author must read the output and set the
> assessment below before this counts as a tested result (see CLAUDE.md, Hard Rules).

## Test Metadata
- **Prompt:** literature/synthesis-across-papers.md
- **Model:** nemotron-3-super-120b
- **Model ID (pinned):** Nemotron-3-Super-120B-A12B-NVFP4
- **Endpoint:** https://copilot-dev.cqls.oregonstate.edu/llm/nemotron3-super-120b-nvfp4/v1
- **Date:** 2026-06-25
- **Tester:** cross-model-harness
- **Assembly strategy:** test-only
- **Temperature:** 0.0

## Test Input Used
Standard test input from prompt file (`## Test Input`).

## Filled Prompt
````
Context: I am synthesizing literature on antibiotic effects on the gut microbiome for a review section. I have read the following papers and am providing summaries below.

Papers provided:

**Paper 1 Summary:**
Anderson et al. (2023). "Broad-spectrum antibiotics cause rapid and persistent microbiome disruption in healthy adults."
- Study: 30 healthy adults given 7-day amoxicillin course
- Finding: 50% reduction in bacterial diversity within 3 days
- Recovery: Partial recovery by 30 days, but some taxa remained depleted at 90 days
- Notable: Proteobacteria expanded during treatment; Bacteroides recovery was slowest

---
**Paper 2 Summary:**
Martinez & Lee (2022). "Microbiome resilience varies by antibiotic class and host factors."
- Study: Meta-analysis of 12 studies (n=340 total subjects)
- Finding: Macrolides caused less diversity loss than fluoroquinolones
- Recovery: Younger subjects (<40) showed faster recovery (mean 21 days vs 45 days)
- Notable: Prior antibiotic exposure associated with slower recovery

---
**Paper 3 Summary:**
Thompson et al. (2024). "Probiotic co-administration does not prevent antibiotic-induced dysbiosis."
- Study: RCT, 60 subjects, probiotic vs placebo during antibiotic treatment
- Finding: No significant difference in diversity loss between groups
- Recovery: Similar recovery trajectories in both arms
- Notable: Probiotic strains did not engraft during antibiotic treatment

Synthesis focus: What is known about microbiome recovery after antibiotic exposure?

My specific research question: Whether there are interventions that could accelerate microbiome recovery.

Task: Synthesize these papers with respect to what is known about microbiome recovery after antibiotic exposure. Structure your synthesis as follows:

1. **Overview**: One paragraph summarizing the collective state of knowledge across these papers.

2. **Points of Agreement**: What do these papers consistently find or conclude? Be specific about which papers support each point.

3. **Points of Disagreement or Tension**: Where do findings, interpretations, or recommendations conflict? Characterize the nature of the disagreement.

4. **Methodological Comparison**: How do the approaches differ? Consider:
   - Study systems/organisms
   - Sample sizes and designs
   - Analytical techniques
   - Outcome measures

5. **Gaps and Limitations**: What questions remain unaddressed across this literature? What limitations are shared?

6. **Synthesis Statement**: Two to three sentences capturing the bottom line for whether there are interventions that could accelerate microbiome recovery.

Constraints:
- Use ONLY information from the papers I have provided
- Do NOT introduce findings, citations, or context from other sources
- When attributing a claim to a paper, be specific (e.g., "Smith et al. found..." not "studies show...")
- If papers contradict each other, present both positions without resolving the disagreement
- If you cannot determine something from the provided texts, state this explicitly

Output format: Use the numbered structure above. For Points of Agreement and Disagreement, use bullet points with specific paper attributions.
````

## Model Output
````


**1. Overview**  
The three papers collectively describe that antibiotic exposure leads to a rapid loss of gut bacterial diversity, followed by a recovery period that is often incomplete and influenced by both drug‑specific and host‑specific factors. While diversity can partially rebound within weeks, certain taxa (e.g., *Bacteroides*) may remain depleted for months, and recovery speed varies with age and antibiotic class. The only tested intervention—probiotic co‑administration—did not alter the trajectory of diversity loss or recovery.

**2. Points of Agreement**  
- **Antibiotic‑induced diversity loss occurs quickly.** Anderson et al. (2023) reported a 50% reduction in bacterial diversity within 3 days of a 7‑day amoxicillin course.  
- **Recovery is gradual and often incomplete.** Anderson et al. (2023) noted partial recovery by 30 days but persistent depletion of some taxa at 90 days; Martinez & Lee (2022) described recovery periods of 21–45 days depending on age; Thompson et al. (2024) observed similar recovery trajectories in probiotic and placebo arms.  
- **Host age influences recovery speed.** Martinez & Lee (2022) found younger subjects (<40 years) recovered faster (mean 21 days) than older subjects (mean 45 days).  
- **Antibiotic class affects the magnitude of disruption.** Martinez & Lee (2022) reported that macrolides caused less diversity loss than fluoroquinolones.  
- **Probiotic co‑administration does not improve outcomes.** Thompson et al. (2024) found no significant difference in diversity loss or recovery between probiotic and placebo groups, and noted that probiotic strains failed to engraft during antibiotic treatment.  

**3. Points of Disagreement or Tension**  
- **Duration of persistent disruption:** Anderson et al. (2023) highlighted that some taxa remained depleted at 90 days, suggesting long‑term effects, whereas Martinez & Lee (2022) emphasized mean recovery times of 21–45 days, implying a shorter window for most subjects. The papers do not directly contradict each other but highlight different aspects (taxon‑specific persistence vs. overall diversity recovery).  
- **Effectiveness of interventions:** Only Thompson et al. (2024) tested an intervention (probiotics) and found it ineffective; the other papers did not evaluate any recovery‑accelerating strategies, leaving open whether other interventions might work.  

**4. Methodological Comparison**  
- **Study systems/organisms:** All three investigations involved human adults; Anderson et al. (2023) used a single‑antibiotic (amoxicillin) trial, Martinez & Lee (2022) synthesized data from multiple studies covering various antibiotic classes, and Thompson et al. (2024) conducted a randomized controlled trial testing probiotic supplementation during antibiotic therapy.  
- **Sample sizes and designs:** Anderson et al. (2023) – prospective cohort, n = 30; Martinez & Lee (2022) – meta‑analysis of 12 studies, total n ≈ 340; Thompson et al. (2024) – RCT, n = 60 (parallel probiotic vs. placebo).  
- **Analytical techniques:** Though not explicitly detailed, each paper relied on sequencing‑based assessment of bacterial community structure (e.g., 16S rRNA gene sequencing) to quantify alpha diversity and taxon abundances.  
- **Outcome measures:** Primary outcomes were changes in bacterial diversity (alpha diversity) and recovery timelines; secondary observations included expansion of Proteobacteria (Anderson et al.), influence of prior antibiotic exposure (Martinez & Lee), and engraftment of probiotic strains (Thompson et al.).  

**5. Gaps and Limitations**  
- **Limited intervention testing:** Only probiotic co‑administration has been evaluated for its capacity to accelerate recovery (Thompson et al., 2024); other potential strategies (e.g., dietary prebiotics, fecal microbiota transplantation, targeted antibiotics) are not addressed.  
- **Antibiotic specificity:** Anderson et al. examined amoxicillin alone; Martinez & Lee aggregated heterogeneous antibiotic classes without isolating effects of individual drugs beyond class‑level comparisons; thus, drug‑specific recovery patterns remain incompletely mapped.  
- **Follow‑up duration:** While Anderson et al. tracked subjects to 90 days, Martinez & Lee reported mean recovery times up to 45 days, and Thompson et al. did not specify post‑treatment observation length, leaving uncertainty about very long‑term (> 6 months) outcomes.  
- **Host heterogeneity:** Age effects were noted (Martinez & Lee), but other host factors (genetics, baseline diet, comorbidities) were not explored across the papers.  
- **Outcome scope:** All studies focused on taxonomic diversity; functional metagenomic or metabolomic consequences of dysbiosis and recovery were not reported.  

**6. Synthesis Statement**  
Current evidence indicates that gut microbiome recovery after antibiotics is variable, often incomplete, and modulated by antibiotic class and host age; the sole tested intervention—probiotic co‑administration—does not accelerate this recovery. Consequently, there is no proven strategy from these studies that reliably speeds microbiome restoration, highlighting a need for further investigation of alternative approaches.
````

## Assessment

_Machine-suggested (UNCONFIRMED) — drafted by Claude Opus 4.7 on 2026-06-26 to speed T4 review. An author must independently read the Model Output above and set the real Recommendation. Anything labeled here is triage, not domain expert review._

**Machine triage:** Output covers all required sections. Complete, no truncation. Concise synthesis. Strong cross-model agreement with peers.

**Suggested verdict (UNCONFIRMED):** Pass

**What still needs human verification:**
- Whether the specific Bacteroides example for persistent depletion is attributed correctly to Anderson et al.
- Spot-check all cited claims against source paper excerpts
- That author/year citations match

## Overall Assessment
- **Recommendation:** PENDING AUTHOR REVIEW
- **Notes:**

## Verification Steps Tested
_Which verification requirements from the prompt were checked, and results._
